Who is sponsoring NCT04075123?

NCT04075123 is sponsored by Canadian Neonatal Network.

What drugs are being tested in NCT04075123?

Interventions in NCT04075123: CPAP.

What condition does NCT04075123 study?

NCT04075123 studies Respiratory Insufficiency Syndrome of Newborn.

Is NCT04075123 still recruiting?

NCT04075123 is currently completed. Last updated 26 April 2023.

Last reviewed 2023-04-26 · How we verify

NCT04075123

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CPAP vs NIPPV: A COMPARATIVE EFFECTIVENESS RESEARCH

Completed Last updated 26 April 2023

What this trial tests

trial testing CPAP in Respiratory Insufficiency Syndrome of Newborn in 1,829 participants. Completed in 30 December 2022.

Timeline

1 October 2019

Primary endpoint
30 December 2021

30 December 2022

Quick facts

Lead sponsor	Canadian Neonatal Network
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,829
Start date	1 October 2019
Primary completion	30 December 2021
Estimated completion	30 December 2022
Sites	1 location across Canada

Drugs / interventions tested

CPAP

Conditions studied

Respiratory Insufficiency Syndrome of Newborn — all drugs for Respiratory Insufficiency Syndrome of Newborn →

Sponsor

Canadian Neonatal Network

Who can join

Adults 23 Weeks to 28 Weeks, any sex, with Respiratory Insufficiency Syndrome of Newborn. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim: Investigators aim is to conduct two complementary and concurrent CER projects using a pragmatic clinical trial design and registry-based RWD to identify the optimal respiratory management practices for extremely preterm neonates and reduce the risk of BPD and SNI. Objectives: Two complementary objectives are proposed. Objective 1: To determine the efficacy and safety of "mandatory non-extubation" until 72 hours of postnatal age for preterm neonates born at 23 -25 weeks' GA who receive mechanical ventilation. Objective 2: To determine whether optimal nasal continuous positive airway pressure post-extubation is as efficacious as nasal intermittent positive pressure ventilation in preterm neonates born at 23 -28 weeks' GA who have received mechanical ventilation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of CPAP

Trials testing the same drug.

NCT07417111 — Continued Pressure for Alveolar Protection (CPAP Trial) · NA · not yet recruiting
NCT07515755 — Supplemental Oxygen and Oxygen Desaturations in Colonoscopies · NA · not yet recruiting
NCT07504926 — A Randomised Feasibility Study of CPAP in Large Airway Collapse · NA · not yet recruiting
NCT07447011 — Glaucoma Respsosne to Lifestyle Corrections in Sleep Apnea · NA · recruiting
NCT07246538 — Positive Airway Pressure (PAP) System Evaluation in Volunteers · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04075123 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Canadian Neonatal Network
Last refreshed: 26 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04075123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing